Table 2.
Baseline Imaging Characteristics of HCC Before TACE
| Imaging Characteristics | All TACE (n=61) |
DEB-TACE (n=42) |
cTACE (n=19) |
p-value |
|---|---|---|---|---|
| Number of target lesionsa | 71 | 49 | 22 | |
| Received prior treatment | 0.392 | |||
| Naïve | 29 (40.8%) | 19 (38.8%) | 10 (45.5%) | |
| Non-naïve | 42 (59.2%) | 30 (61.2%) | 12 (54.5%) | |
| Tumor burden | ||||
| Single | 33 (54.1%) | 21 (50.0%) | 12 (63.2%) | 0.463 |
| Multifocal | 26 (42.6%) | 20 (47.6%) | 6 (31.6%) | |
| Infiltrating | 2 (3.3%) | 1 (2.4%) | 1 (5.3%) | |
| Tumor location | ||||
| Unilobar | 44 (72.1%) | 29 (69.0%) | 15 (78.9%) | 0.544 |
| Bilobar | 17 (27.9%) | 13 (31.0%) | 4 (21.1%) | |
| Tumor number | 2.4±2.1 | 2.2±1.8 | 2.7±2.7 | 0.465 |
| Mean target lesions size (cm) | 4.84±4.30 | 4.83±4.55 | 4.87±3.76 | 0.970 |
| Macroscopic PVTT | 0.921 | |||
| None | 49 (80.3%) | 34 (81.0%) | 15 (79.0%) | |
| Vp2 | 4 (6.6%) | 2 (4.8%) | 2 (10.5%) | |
| Vp3 | 8 (13.1%) | 6 (14.2%) | 2 (10.5%) |
Note: aThe preTACE imaging characteristics of target lesions were confirmed retrospectively based on DSA or CBCT findings during TACE.
Abbreviations: cTACE, conventional transarterial chemoembolization; DEB-TACE, drug-eluting beads transarterial chemoembolization; HCC, hepatocellular carcinoma; PVTT, portal vein tumor thrombosis; TACE, transarterial chemoembolization.